Welcome to the Neuro-SysMed monthly seminar series! Speakers January 10th are Ole-Bjørn Tysnes and Tale Bjerknes who will talk about current ALS-studies at Neuro-SysMed. You are also invited to an informal networking lunch before the seminar (lunch 11.30-12.00). No charge, just remember to register.
Topic: ALS – update on genetics, biomarkers and clinical studies at Neuro-SysMed.
Speakers: Ole-Bjørn Tysnes and Tale Bjerknes
Place: The auditorium in Armauer Hansens Hus (campus Haukeland University Hospital, Bergen)
Time: Wednesday January 10, 2024, at 11:30–13:00 (lunch 11:30–12:00).
Registration: please use this link.
Abstract: Tale Bjerknes and Ole-Bjørn Tysnes will talk about current ALS-studies at Neuro-SysMed. The ALS node at Neuro-SysMed has one clinical trial on therapeutic intervention, the NO-ALS trial, which has currently included more than 250 patients. This study is focusing on the effect of a combination of nicotineamide riboside and pterostilbene in ALS. They are also organising a clinical study on the quality of life upon decisions of life-prolonging respiratory treatment in ALS. The effect of such discussions on quality of life of patients and their families has not been well studied in ALS. Both studies are national studies including patients from all over Norway.
Tale and Ole-Bjørn will also talk about the rationale behind the ALS node’s treatment study, give us the news on genetics of ALS in Norway, and present upcoming ALS biomarkers. These biomarkers may be useful in diagnosing ALS, but will probably be even as important when studying the effect of study drugs in ALS trials. Convincing data show that the level of neurofilament light chain in the blood represent a prognostic marker and a marker for therapy effect in ALS.